SIGN: a Phase II, open-label, randomized study comparing gefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

被引：1
|
作者：
Cufer, T
Vrdoljak, E
机构：
[1] Clin Hosp Split, Split, Croatia
[2] Inst Oncol, Ljubljana, Slovenia
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80403-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [1] Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
    Cufer, Tania
    Vrdoljak, Eduard
    Gaafar, Rabab
    Erensoy, Inci
    Pemberton, Kristine
    ANTI-CANCER DRUGS, 2006, 17 (04) : 401 - 409
  • [2] Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
    Cufer, T
    Vrdojak, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 629S - 629S
  • [3] A randomized Phase II trial of docetaxel alone and in combination with gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer
    Robinet, G
    Falchero, L
    Perol, M
    Thomas, P
    Monnet, I
    Grivaux, M
    Crequit, J
    Letreut, J
    Paillotin, D
    Chouaid, C
    LUNG CANCER, 2005, 49 : S33 - S33
  • [4] A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer
    Zhefeng Liu
    Zhimin Wei
    Yi Hu
    Feng Gao
    Lu Hao
    Ping Fang
    Shengjie Sun
    Jinyu Li
    Shunchang Jiao
    Medical Oncology, 2015, 32
  • [5] A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer
    Liu, Zhefeng
    Wei, Zhimin
    Hu, Yi
    Gao, Feng
    Hao, Lu
    Fang, Ping
    Sun, Shengjie
    Li, Jinyu
    Jiao, Shunchang
    MEDICAL ONCOLOGY, 2015, 32 (08)
  • [6] Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study
    G. Robinet
    F. Barlesi
    P. Fournel
    H. Berard
    R. Corre
    A. Vergnenegre
    L. Falchero
    P-J. Souquet
    A. Tisseron-Carrasco
    C. Chouaid
    Targeted Oncology, 2007, 2 : 63 - 71
  • [7] Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study
    Robinet, G.
    Barlesi, F.
    Fournel, P.
    Berard, H.
    Corre, R.
    Vergnenegre, A.
    Falchero, L.
    Souquet, P-J.
    Tisseron-Carrasco, A.
    Chouaid, C.
    TARGETED ONCOLOGY, 2007, 2 (02) : 63 - 71
  • [8] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
    Kelly, R. J.
    Shepherd, F. A.
    Krivoshik, A.
    Jie, F.
    Horn, L.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1127 - 1133
  • [9] Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer -: A phase II study
    Cao, MG
    Aramendía, JM
    Salgado, E
    Aristu, J
    Monje, RM
    Algarra, SM
    Ordoñez, JM
    Brugarolas, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (05): : 480 - 484
  • [10] A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Berge, Eamon M.
    Doebele, Robert C.
    Ballas, Marc S.
    Jahan, Thierry
    Haigentz, Missak, Jr.
    Hoffman, David
    Spicer, James
    West, Howard
    Lee, Pablo
    Yang, Ling
    Joshi, Adarsh
    Gao, Ling
    Yurasov, Sergey
    Mita, Alain
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1532 - 1539
12345